After a depressing 2024, TransMedics Group stock is surging in 2025. Shares of TransMedics Group (NASDAQ: TMDX) recently ...

This performance was driven by strong demand in cardiopulmonary products, particularly the Essenz Perfusion System, and modest growth in neuromodulation across Europe and other global markets.

More than half a century after the world’s first heart transplant, scientists are finding fascinating ways to improve the ...

Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance ...

The Andover, Massachusetts–based medtech company, which offers an organ care system (OCS) for transplant therapy, hit $143.5 ...

Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the ...

The Organ Transport Devices Market is segmented by devices, disposables, perfusion solutions, and region from 2025 to 2035 ...

TransMedics Group, Inc.’s TMDX share price has surged by 21.55%, which has investors questioning if this is right time to sell.

Brain tumors strike over 25,000 Americans annually with often subtle warning signs. Learn crucial facts about detection, ...

We came across a bullish thesis on TransMedics Group, Inc. (TMDX) on Substack by Oliver | MMMT Wealth. In this article, we ...